OIG Advisory Opinion: 24-05

    Unfavorable

    Patient travel and fertility preservation subsidies for $2M gene therapies

    Recorded opinion date:

    The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.

    What OIG Said

    OIG split its opinion: it approved the travel support, but flagged the fertility payments as potential inducement, with no FMV, no defensibility, and no exception.

    ⚠OIG reviewed a biotech company’s plan to offer two types of support to patients prescribed $2M+ gene therapies: (1) travel + lodging + meals, and (2) up to $22,500 for fertility preservation.

    ⚠The travel support was found FAVORABLE because it was means-tested, clearly scoped, backed by documentation, and designed to remove access barriers, not drive referrals.

    ⚠The fertility support was deemed UNFAVORABLE: OIG said it likely constitutes prohibited remuneration, could influence product choice, and lacked FMV or commercial reasonableness guardrails.

    ⚠OIG emphasized that high-dollar patient assistance can cross the line if it isn’t independently valued, commercially necessary, and defensible as access-enabling, not steerage.

    Diligence Checklist

    What you need to be ready to show in diligence

    ✓Have clear documentation of how all support payments are structured, capped, and means-tested.

    ✓Prove support is for access, not loyalty, product selection, or referral pathways.

    ✓Show that all dollar amounts are independently valued or benchmarked, especially if over $10K.

    ✓Keep records of efforts to confirm third-party coverage was exhausted before offering support.

    ✓Do not rely on “financial need” alone, OIG said that’s not enough to justify value transfer.

    If you’re offering high-dollar patient support without FMV grounding, commercial necessity, and defensibility, you are squarely in the risk profile OIG flagged as inducement.

    Structure not diligence-ready?

    Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.

    Original PDF cover text

    UNFAVORABLE

    OIG WATCH 24-05

    Patient travel and fertility preservation subsidies for $2M gene therapies

    Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.

    Source documents

    Preparing document preview…

    Ready to Move Forward?

    Let's explore how we can support your goals